每周股票复盘：华熙生物（688363）发酵法软骨素钠完成医疗器械主文档登记

Core Viewpoint - Huaxi Biological has successfully registered its fermentation-derived sodium chondroitin sulfate with the National Medical Products Administration, marking it as the first company in China to achieve compliance for this product [1][4] Company Announcements - Huaxi Biological's fermentation-derived sodium chondroitin sulfate has completed the main document registration for medical devices, allowing it to be used in Class II and III medical devices, potentially providing core materials for high-end medical equipment [1][4] - The controlling shareholder, Huaxi Xinyu Investment Co., Ltd., plans to increase its stake in Huaxi Biological by investing between RMB 200 million and RMB 300 million over the next six months, with a maximum purchase price of RMB 70 per share [3][4] Market Context - Traditional chondroitin sulfate is extracted from animal cartilage, which poses issues such as immunogenicity, unsustainable sourcing, and high pollution from extraction processes. The company aims to leverage synthetic biology technology to develop chondroitin sulfate raw materials for ophthalmology, orthopedics, and medical aesthetics [2]